Shares of GenVec Inc (NASDAQ: GNVC), engaged in developing gene-based pharmaceuticals and therapies for the treatment of major medical needs, recorded over 23.0% gain during each of the past two consecutive trading sessions with significant number of shares exchanging hands. GNVC was among the top performers in the U.S healthcare sector after gaining 25.8% and closed at $3.55 Thursday, while recording significant trading volumes of 502,047 shares. During the past 5-trading sessions, GNVC gained 70.7% with daily average trading volumes of 192,853 shares, while the stock accumulated 74.0% gain during the past one month with daily average trading volumes of 70,144 shares. The stock is up 70.7% year-to-date.
Company Description:
GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company developing novel therapeutic drugs and vaccines. The company specializes in the treatment of cancers, including pancreatic cancer, esophageal cancer, rectal cancer, and head and neck cancer. The company is also involved in studies involving hearing loss and balance disorders. GenVec also develops vaccines for infectious diseases.
1-Year Stock Chart:
Source: Bloomberg
